Tumor Necrosis Factor-[alpha] Promoter Polymorphism at Position -308 Predicts Response to Combination Therapy in Hepatitis C Virus Infection
16th Nov 2005, 21:23 GMT
The G→A transition in the tumor necrosis factor (TNF)–α promoter region at position −308 (TNF308.2) and −238 (TNF238.2) were determined in 141 patients with chronic hepatitis C virus (HCV) infection. Patients received combination therapy with high-dose interferon (IFN)–α and ribavirin for 24 weeks. A total of 100 patients (70.9%) had a sustained virologic response (SVR) after treatment. The TNF308.2 allele was independently associated with an SVR, particularly in patients with HCV genotype 1b infection and >200,000 IU of HCV RNA/mL in serum. In conclusion, the response to combination therapy with high-dose IFN-α and ribavirin may be associated, at least in part, with host genetic factors.
Tumor Necrosis Factor-[alpha] Promoter Polymorphism at Position -308 Predicts Response to Combination Therapy in Hepatitis C Virus Infection related news:
- Largest hepatitis-C U.S. study defines optimal therapy — News-Medical News Feed
- NewYork-Presbyterian/Weill Cornell: Largest Hepatitis C Trial in U.S. Patients Shows Weight-Based REBETOL in Combination With PEG-INTRON Increases Sustained Response, Lowers Relapse — Market Wire - Pharmaceuticals and Biotech
- Hepatitis treatment studies' results announced — OnMedica Latest News
- SciClone Announces Data Presentations at AASLD Regarding ZADAXIN's Activity in Hepatitis B — Operations-Related News from StratCenter.com
- Biotech cancer therapy gets approval in China — Business - International Herald Tribune
- Positive phase I trial for Schering-Plough HCV treatment — Pharmaceutical Business Review Online
- China Approves a Selective Cancer Drug — NYT > Health
- Volume 41, number 12: Spontaneous Hepatic Decompensation in Patients Coinfected with HIV and Hepatitis C Virus during Interferon-Ribavirin Combination Treatment — Clin Infect Dis Latest Issue
- Role of Nucleic Acid Testing in Cadaver Organ Donor Screening: Detection of Hepatitis C Virus RNA in Seropositive and Seronegative Donors — Medscape Gastroenterology Headlines
- AASLD: Peg-Interferon and Ifn-Ribavirin Combo Keep HCV in Check Long Term — MedPage Today Infectious Disease